Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations: A phase 2 study.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2016 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Safety and efficcay results of erlotinib monotherapy presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 19 Apr 2013 New trial record